SUTRO
Live / Applied — Second extension granted (statement of use) (as of 24 Feb 2026)
What this means for you
Not registered yet, but its 12 Aug 2024 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98694731
- Mark type
- Stylized text
- Filed
- 12 Aug 2024
- Published for opposition
- 27 May 2025
- Attorney of record
- Karen Won
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical and biological preparations for the immune system targeting immuno-oncology pathways; Pharmaceutical and biological preparations for use in oncology; Pharmaceuticals and biological preparations for prophylactic, diagnostic, and therapeutic use in treating, preventing, and managing cancer; Therapeutic agents for medical use, namely, proteins and derivatives, antibody-drug conjugates, immunostimulatory antibody-drug conjugates, dual conjugates, cytokines, bispecific antibodies, and engineered antibodies for destroying tumor cells and stimulating immune response; Vaccines; Bacterial lysate preparations and bacterial extract preparations, for use in the cell free production of therapeutic proteins and peptides for medical use
- Class 040 — Treatment of materials: Custom manufacturing of pharmaceuticals and therapeutic agents for medical use; Custom manufacturing of bacterial lysate preparations and bacterial extract preparations.
- Class 042 — Scientific and technological services: Research and development in the fields of pharmaceuticals, biologics, chemistry, protein engineering, proteins and derivatives, antibody-drug conjugates, immunostimulatory antibody-drug conjugates, dual conjugates, cytokines, bispecific antibodies, engineered antibodies, oncology, and immunology; Providing medical scientific research information in the fields of pharmaceuticals, biologics, chemistry, protein engineering, proteins and derivatives, antibody-drug conjugates, immunostimulatory anti-drug conjugates, cytokines, bispecific antibodies, engineered antibodies, oncology, and immunology; Drug discovery, custom design, and development services featuring therapeutic agents for the treatment and prevention of diseases.
Owner
- Sutro Biopharma, Inc., South San Francisco, CA, US
- Sutro Biopharma, Inc., South San Francisco, CA, US
Prosecution history
- 25 Feb 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 24 Feb 2026 — TEAS STATEMENT OF USE RECEIVED
- 24 Feb 2026 — SOU EXTENSION 2 GRANTED
- 24 Feb 2026 — SOU EXTENSION 2 FILED
- 24 Feb 2026 — SOU TEAS EXTENSION RECEIVED
- 17 Jan 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 16 Jan 2026 — SOU EXTENSION 1 GRANTED
- 16 Jan 2026 — SOU EXTENSION 1 FILED
- 16 Jan 2026 — SOU TEAS EXTENSION RECEIVED
- 22 Jul 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 27 May 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 27 May 2025 — PUBLISHED FOR OPPOSITION
- 21 May 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 25 Apr 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 22 Apr 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED